Precision BioSciences, Inc. (DTIL) Key Metrics
DTIL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $159.3M
- Enterprise value
- $116.1M
- P/E (TTM)
- —
- Forward P/E
- 11.8
- PEG ratio
- —
- Price / sales
- 3.5
- Price / book
- 3.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.27
DTIL key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDTIL valuation Price multiples at each fiscal year-end price.
Price / sales+307.9%
1.6
2025 · hover or tap a bar for each year
20162025
Price / book+24.4%
0.6
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+100.2 pts
−123.6%
2025 · hover or tap a bar for each year
20162025
DTIL returns How much profit the business earns on the capital it uses.
Return on equity−80.6 pts
−61.5%
2025 · hover or tap a bar for each year
20162025
Return on assets−36.3 pts
−31.4%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−107.0 pts
−192.4%
2025 · hover or tap a bar for each year
20162025
Asset turnover−49.2%
0.24
2025 · hover or tap a bar for each year
20162025
DTIL per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−73.2%
$2.67
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$3.56
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$5.14
2025 · hover or tap a bar for each year
20162025
Book value per share−12.2%
$7.19
2025 · hover or tap a bar for each year
20162025
Shares outstanding+86.3%
12.8M
2025 · hover or tap a bar for each year
20162025
DTIL financial health Debt, liquidity and how easily interest is covered.
Debt / equity−41.4%
0.31
2025 · hover or tap a bar for each year
20162025
Net debt−$30.5M
−$86.8M
2025 · hover or tap a bar for each year
20162025
Current ratio+110.1%
13.32
2025 · hover or tap a bar for each year
20162025
Interest coverage
-36.7
2025 · hover or tap a bar for each year
20162025
Debt / assets−15.3%
0.19
2025 · hover or tap a bar for each year
20162025
DTIL efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−29 days
9 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−64 days
107 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+35 days
-98 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−0.1 pts
0.2%
2025 · hover or tap a bar for each year
20162025
DTIL valuation history
Fiscal year-endToday10-year median
DTIL returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DTIL debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DTIL cash returned to shareholders
DividendsBuybacksFree cash flow
DTIL price vs earnings per share
Share price at year-endEPS (right axis)
DTIL key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $53.4M | $26.2M | — | — | — | — | — | — | — | — |
| Enterprise value | −$33.4M | −$30.0M | — | — | — | — | — | — | — | — |
| P/E ratio | — | 3.7 | — | — | — | — | — | — | — | — |
| Price / sales | 1.6 | 0.4 | — | — | — | — | — | — | — | — |
| Price / book | 0.6 | 0.5 | — | — | — | — | — | — | — | — |
| EV / sales | -1.0 | -0.4 | — | — | — | — | — | — | — | — |
| Earnings yield | −85.7% | 27.3% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −123.6% | −223.8% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $4.16 | $3.81 | $10.95 | $35.70 | $222.00 | $250.20 | $416.70 | — | — | — |
| Per share | ||||||||||
| Revenue per share | $2.67 | $9.98 | — | — | — | — | — | — | — | $0.42 |
| Earnings per share | −$3.56 | $1.04 | — | — | — | — | — | — | — | −$0.49 |
| Operating cash flow per share | −$5.13 | −$8.49 | — | — | — | — | — | — | — | $5.51 |
| Free cash flow per share | −$5.14 | −$8.53 | — | — | — | — | — | — | — | $5.39 |
| Cash per share | $9.01 | $12.54 | — | — | — | — | — | — | — | $5.58 |
| Book value per share | $7.19 | $8.19 | — | — | — | — | — | — | — | −$0.28 |
| Tangible book value per share | $7.10 | $8.10 | — | — | — | — | — | — | — | −$0.30 |
| Dividends per share | — | — | — | — | — | — | — | — | — | $0.74 |
| Capex per share | $0.01 | $0.04 | — | — | — | — | — | — | — | $0.12 |
| Debt per share | $2.25 | $4.36 | — | — | — | — | — | — | — | — |
| Shares outstanding | 12.8M | 6.9M | — | — | — | — | — | — | — | 16.7M |
| Change in shares outstanding | +86.3% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −61.5% | 19.0% | −154.7% | −147.3% | −45.1% | −119.3% | −104.2% | −677.5% | — | — |
| Return on assets (ROA) | −31.4% | 4.8% | −30.8% | −49.7% | −16.9% | −56.6% | −49.7% | −43.6% | −24.7% | −8.4% |
| Return on tangible assets | −29.8% | 5.3% | −38.5% | −47.0% | −14.6% | −73.3% | −39.7% | −33.6% | −29.1% | −8.4% |
| Free cash flow margin | −192.4% | −85.4% | −177.3% | −195.5% | −14.4% | −380.6% | −442.0% | −619.3% | −458.6% | — |
| Income quality (OCF / net income) | — | −8.15 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $28.8M | $30.0M | $31.3M | $25.0M | $9.1M | $10.5M | $6.8M | $3.3M | $1.5M | — |
| Cash & short-term investments | $115.6M | $86.3M | $116.7M | $189.6M | $143.7M | $89.8M | $180.9M | $103.2M | $62.8M | $93.4M |
| Net debt | −$86.8M | −$56.3M | −$85.4M | −$164.6M | −$134.6M | −$79.3M | −$174.1M | −$99.9M | −$61.3M | −$93.4M |
| Debt / equity | 0.31 | 0.53 | 1.66 | 0.41 | 0.10 | 0.24 | 0.05 | 0.08 | — | — |
| Debt / assets | 0.19 | 0.22 | 0.20 | 0.10 | 0.04 | 0.07 | 0.03 | 0.02 | 0.02 | — |
| Net debt / EBITDA | — | −4.16 | — | — | — | — | — | — | — | — |
| Current ratio | 13.32 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 | 7.19 | 8.22 | 6.99 | 11.32 |
| Quick ratio | 13.32 | 6.34 | 2.73 | 3.21 | 4.01 | 2.33 | 6.84 | 8.22 | 6.99 | 11.32 |
| Interest coverage | -36.7 | -14.7 | -19.6 | -56.1 | -298.3 | -133.6 | -479.1 | — | — | — |
| Working capital | $109.8M | $80.0M | $86.4M | $139.4M | $125.8M | $62.7M | $166.7M | $101.6M | $55.1M | $86.1M |
| Invested capital | $5.5M | $126,000 | −$66.5M | −$104.2M | −$43.4M | −$34.9M | −$35.7M | −$60.0M | −$87.7M | −$98.2M |
| Tangible asset value | $91.1M | $55.8M | $18.5M | $59.7M | $89.1M | $43.1M | $136.9M | $38.5M | −$26.5M | −$5.0M |
| Net current asset value | $56.6M | $15.0M | −$4.6M | $21.4M | $41.4M | −$169,000 | $96.8M | $17.0M | −$34.7M | −$8.8M |
| Graham number | — | $13.85 | — | — | — | — | — | — | — | — |
| Graham net-net per share | $4.16 | $1.10 | — | — | — | — | — | — | — | −$0.56 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | — | $12.4M |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $952,000 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | — | 13.8% |
| Capex / revenue | 0.2% | 0.4% | 4.7% | 13.2% | 5.0% | 20.7% | 110.9% | 144.1% | 85.8% | 29.6% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | — | 2.2% |
| Capex / depreciation | 0.03 | 0.05 | 0.28 | 0.37 | 0.57 | 0.51 | 4.64 | 6.66 | 3.88 | 3.24 |
| Stock-based compensation / revenue | 29.7% | 18.3% | 28.8% | 76.5% | 14.3% | 56.8% | 40.2% | 22.5% | 6.5% | — |
| R&D / revenue | 158.1% | 86.7% | 109.5% | 183.8% | 99.7% | 403.8% | 370.6% | 414.6% | 313.4% | 129.8% |
| SG&A / revenue | 94.1% | 51.4% | 80.2% | 164.5% | 34.3% | 148.5% | 121.5% | 125.6% | 123.6% | 87.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 9.0 | 38.5 | 50.6 | 8.8 | 16.6 | 82.4 | 12.2 | 9.1 | 11.5 | 20.1 |
| Days of inventory on hand | — | — | — | 506.4 | — | — | — | — | — | — |
| Days payables outstanding | 106.6 | 170.7 | 80.1 | 36.4 | — | — | — | — | — | — |
| Cash conversion cycle (days) | -97.6 | -132.1 | -29.4 | 478.8 | — | — | — | — | — | — |
| Receivables turnover | 40.36 | 9.48 | 7.21 | 41.55 | 22.03 | 4.43 | 29.89 | 39.94 | 31.78 | 18.17 |
| Payables turnover | 3.42 | 2.14 | 4.56 | 10.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | 0.72 | 0.00 | 0.00 | 0.00 | — | — | — |
| Asset turnover | 0.24 | 0.46 | 0.24 | 0.11 | 0.64 | 0.13 | 0.12 | 0.10 | 0.08 | 0.07 |
| Average receivables | $849,000 | $7.2M | $6.8M | $604,000 | $5.2M | $5.5M | $744,000 | $272,500 | $204,000 | $386,000 |
| Average payables | $804,000 | $2.1M | $1.8M | $898,500 | $968,000 | $1.4M | $2.1M | $2.0M | $1.5M | $1.3M |
| Average inventory | — | — | — | $12.5M | $11.6M | $7.6M | $9.5M | — | — | — |
| Intangibles / total assets | 0.8% | 0.5% | 0.3% | 0.3% | 1.0% | 0.9% | 0.6% | 1.1% | 0.1% | 0.3% |
Computed from DTIL's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DTIL valuation and financial ratios
Precision BioSciences earned a return on equity of −61.5% in fiscal 2025. It ended the year with $28.8 million of debt and $115.6 million in cash and short-term investments, a net cash position of $86.8 million. The share count fell 23.4% from 16.7M to 12.8M over 9 years.
See the DTIL income statement, the DTIL chart for price history, or the DTIL stock overview for the latest quote and news.
DTIL key metrics FAQ
What is Precision BioSciences's return on equity?
Precision BioSciences's return on equity (ROE) was −61.5% in fiscal 2025: net income of -$45.7 million on average shareholders' equity of $74.3 million.
How much debt does Precision BioSciences have?
Precision BioSciences had total debt of $28.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.31 and more cash than debt.
What is Precision BioSciences's free cash flow yield?
Precision BioSciences generated -$65.9 million of free cash flow in fiscal 2025, a free cash flow yield of −123.6% on its market value at year-end ($53.4 million).
What is Precision BioSciences's current ratio?
Precision BioSciences's current ratio was 13.32 at the end of fiscal 2025: current assets were 13.32 times current liabilities.